Taipei Medical University
This year, top academic institute in Taiwan - Taipei Medical University Office of Business Development has brought their top research team to demonstrate their latest research updates and the highlights of Taiwan Medical University: 
 
Associate professor Kuo-Hsiang Chuang shared 4 technical highlights:
 
1. Improved Safety and efficiency in CAR T Cell Therapy - A novel bispecific antibodies technology
 
The laboratory team from Professor Chuang developed a bispecific antibodies technical platform, which could one-step differentiate, expand, and arm T cell. It is an innovative bispecific antibodies (BsAb) that co-cultured BsAb with the peripheral blood mononuclear cells (PBMCs) separated from the cancer patients and converted PBMCs to tumor specific T cells less than 10 days and injected to the patients to treat. In terms of the security, compared to the traditional CAR-T cell therapies which using retroviral transfection and making the transformed T cells have the higher risk of canceration and may even fuse with cancer cells to form more malignant cancer cells, this method is faster and safer without using retroviral transfection. It has applied for the PCT Patent Cooperation Agreement and is currently deploying a global patent. It is currently effective in animal studies and looking to get into the pre-clinical trials soon.
 
2. Novel Poly-Peptide Could Dramatically Enhance the Sensitivity of Immunoassay
 
Professor Chuang mentioned that the present immunoassays, such as Enzyme-linked immunosorbent assay, ELISA or Western Blot, it all has a problem of lacking of the sensitivity. Therefore, they developed a recombinant protein, named poly-peptide, which can specifically trap antibodies. By mixing poly-peptide with detection antibodies, it can increase the signal strength significantly and dramatically enhance the sensitivity of detection based on the various immunoassay. Professor Chuang and his team have filed the patent applications in Taiwan (ROC/106123547) and USA (USA/15/649,184) to protect this invention.
 
3. The Transgenic Mouse can Significantly Reduce the Cost on Drug Development 
 
The biggest dilemma in the development of type 1 diabetes (T1D) is the animal model. The rate and the time point of NOD mice were quite different, which required lots of mice during the pharmaceutical research development in the laboratory. Therefore, Professor Chuang’s team and Professor Tain-Lu Cheng from Kaohsiung Medical University developed a NOD/ plns-aPEG mouse. NOD/ plns-aPEG mice specifically express an anti-PEG reporter on the surface of its pancreatic islets, which can conveniently monitor the survival of islets without animal sacrifice by using PEGylated imaging probes combined with the various noninvasive imaging system. We have filed the patent applications in Taiwan (ROC/ 105139336) and USA (USA/15/364,228) to protect this invention.  
 
4. The Antibody Technique Debunked the Myth in Tumor Microenvironment
 
Professor Chuang said that the biggest difficulty with the current antibody drugs for treating tumors is the tumor fibroblasts in the tumor microenvironment, which provided a physical barrier formed by collagen and fibrosis to protect tumor, resulting in low cytotoxic efficiency of nanomedicine. Professor Chuang and Taipei Medical University (Professor Ming-Thau Sheu and Yuan-Soon Ho), Kaohsiung Medical University (Professor Tain-Lu Cheng), and the Academia Sinica (researcher Dr. Roffler, Steve R.) jointly developed trispecific antibodies (TsAbs) that can bind tumor, anti-tumor-associated fibroblast (TAF), and anti-cancer drugs. TsAbs can simultaneously target tumors, TAF, and anti-cancer drugs, thus dramatically optimize the therapeutic efficacy of anti-cancer drugs.
 
Microfluidic chips for acquiring sperms with high motility, productions and applications
Associate professor Li-Chern Pan invented a microfluidic chips device which could obtain high-quality spermatozoa. Based on a progressive enlargement design, the current device is capable of providing a channel structure that built around sperms’ intrinsic swim against incoming flow property and collected spermatozoa that swim against a preset velocity threshold. Meanwhile, debris and slower moving sperms will move in direction of flow stream towards a waste reservoir. Therefore, it can simulate the sperm activation process of the genital tract in the body, and thus obtain the sperm with high motility. The glass used in the microfluidic chips have passed the biosafety, genotoxicity and micronucleus tests in accordance with the US FDA specifications, and the outer packaging has also completed sterilization tests and residual toxicity tests. This technology granted for the patent application in TW and CN and republic of PCT (US and EU).
 
The Hydrogen Rich Water is Effective in the Animal Disease Models
 
Professor Yu-Chuan Liu indicated that mostly people would take the health food because they pursued health and longevity. Instead of the different effectiveness of taking the health food from individuals, water is the daily life drink. Therefore, he and his team used resonance light to activate the nanogold, and implement the energy and anti-inflammatory factor to water, which could reduce the hydrogen bond of water and affect the molecular structure and quality to generate the plasmon-induced activated water with anti-oxidation, as know as hydrogen rich water. Professor Liu said that the hydrogen rich water have the energy to against the inflammation and enhance the metabolism, strengthen the immune system. In terms of the animal trials, they cooperated with the hospitals to proceed 8 animal disease models, including Alzheimer's disease, Parkinson’s disease, sleep deprivation, lung cancer, renal dysfunction. It has been established and fully protected in USA and Taiwan, also filed the patent applications in Japan, EU and China, hoped to help more people and advance the health and life quality in the future.
 
Novel HDAC Inhibitor for Ischemic Stroke and Dementia in Animal Studies
 
Professor Kuo-Sheng Hung invented a novel small molecular compound MPT0E014 for subtype-selective histone deacetylase inhibitor (HDACI) in neurological disease therapeutics. They have successfully demonstrated the efficacy of MPT0E014 in dementia and ischemic stroke in animal studies. The treatment for this new drug can be extended to 24 hours after stroke from the previously known as 3 hours. Besides, in the experiment of dementia rats, it can also slow down the progress of the disease and recovery its intelligence. MPT0E01 has been established and fully protected by intellectual property. They have obtained patents from USA, EU,  Japan, Taiwan, Russia, Korea, China,  Australia,Mexico, Indonesia, Canada etc.
 
The Academic Value is Unlimited, Expecting to Commercialize It
 
The seven studies published by the four professors and their research teams from Taipei Medical University undoubtedly enhanced the international academic reputation of Taipei Medical University. In the future, Taipei Medical University Office of Business Development expects to commercialize more research results successfully as well as promote the industry-university communication and development in the biotechnology field. Therefore, in order to achieve the concept of sustainable operation, a well-established ecosystem of biotechnology is the key.

本網站使用您的Cookie於優化網站及您的瀏覽經驗。繼續瀏覽網站即表示您同意本公司隱私權政策,您可至隱私權政策了解詳細資訊。